Abstract: The present disclosure relates to tryptamine compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, polymorphs, or prodrugs thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases such as those diseases associated with a 5-HT2 receptor.

Abstract: Provided herein are injectable pharmaceutical formulations, methods for their production, kits, and uses thereof in the treatment of diseases or disorders. The injectable pharmaceutical formulations include a psychopharmaceutical agent, a release modifier, and an aqueous vehicle. The pharmaceutical formulations allow for a time-restricted temporal controlled-release of the psychopharmaceutical agent upon administration by injection such as subcutaneous injection. The diseases or disorders treatable with the pharmaceutical formulations include, for example, neuropsychiatric diseases or disorders or inflammatory diseases or disorders, such as a central nervous system (CNS) disorder and/or psychological disorder, including those associated with a 5-HT2 receptor.

Abstract: Provided are methods for delivering psychedelic drugs to a patient in need thereof comprising administering via inhalation of a psychedelic drug in the form of an aerosol, methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of a psychedelic drug in the form of an aerosol, devices for delivery of psychedelic drug and nitrous oxide mixtures by inhalation, including with remote activation and control, and methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation of nitrous oxide/oxygen mixtures having an amount of nitrous oxide of 15 to 25% by volume of total gas.

Abstract: The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.

Abstract: The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases associated with a 5-HT2 receptor.

Abstract: Combination drug therapies comprising a 5-HT2A receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, xenon, argon, ketamine, etc.) are provided. Also described are pharmaceutical compositions and methods of treating a central nervous system (CNS) disorder or a psychiatric disease using the combination drug therapy, for example, via aerosol inhalation.

Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Abstract: The present disclosure provides a tobacco-free oral delivery product comprising a pouch having a first sheet and a second sheet joined together to form an interior space, a first component disposed within the interior space comprising tobacco-free nicotine and a first sorbent, and a second component disposed within the interior space comprising methyl salicylate and a second sorbent different from the first sorbent. The first component and second component are configured to provide sustained release of the tobacco-free nicotine and methyl salicylate over a period of at least 60 minutes, with the tobacco-free nicotine maintaining a release concentration of at least 700 ?g/pouch at 60 minutes and the flavor component maintaining a release concentration of at least 600 ?g/pouch at 60 minutes.

Abstract: The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: The present disclosure relates to stable pharmaceutical compositions of amorphous psilocybin and deuterated psilocybin, and to the use of such pharmaceutical compositions in the treatment of diseases associated with a serotonin 5-HT2 receptor. The pharmaceutical compositions are formulated with solid dispersions of psilocybin or deuterated psilocybin in amorphous form dispersed in a polymer.

Abstract: The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

Abstract: There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: The present invention is directed to methods of producing THC from CBD utilizing non-harsh methodology and resulting in substantially increased yields, as well as devices built upon these novel methods. The methods and devices are material efficient, and in certain embodiments, solvent-free. In particular, in certain embodiments, these methods and related devices are suitable for commercial production of THC from CBD. Furthermore, in certain embodiments, the present invention provides methods of producing THC from CBD in manner that affords tunability to select the ratio of THC-8 to THC-9.

Abstract: The present disclosure relates to pharmaceutical compositions formulated with psilocin and/or deuterated psilocin compounds or pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, and an organic acid agent as a pharmaceutically acceptable vehicle. Uses in the treatment of diseases, such as those associated, with a 5-HT2 receptor, are also disclosed.

Abstract: Provided are methods for delivering psychedelic drugs such as tryptamine psychedelics to a patient in need thereof via inhalation. The psychedelic drug is delivered in the form of an aerosol, such as a mist or a dry powder. Methods for treating a central nervous system (CNS) disorder or psychological disorder via inhalation routes are provided.

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.